| 1 |
NCT03300934 |
Recruiting |
Adolescence and Diabetes:Can an Automated Closed Loop System Improve Control ? |
|
- Device: automated closed loop glucose control
|
Interventional |
Not Applicable |
- Centre Hospitalier du Luxembourg
- University of Cambridge
- Luxembourg Institute of Health
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Time spent in glucose target (%) (3.9 - 10 mmol/l)
- Time spent below glucose target (%) (<3.0mmol/l and < 2,5 mmol/l)
- Time spent above glucose target (%) (> 10 mmol/l)
- (and 7 more...)
|
14 |
All |
12 Years to 18 Years (Child, Adult) |
NCT03300934 |
Spidiman |
SPIDIMAN2 |
July 1, 2017 |
July 1, 2018 |
September 1, 2018 |
October 4, 2017 |
October 4, 2017 |
|
- Clinique des Enfants CHluxembourg
Luxembourg, Luxembourg
|
| 2 |
NCT03286023 |
Recruiting |
Stereotactic Radiotherapy for Brain Metastases |
|
- Radiation: stereotactic radiotherapy
|
Observational |
|
- Centre Francois Baclesse, Luxembourg
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Evaluation of tumoral response
- Evaluation of toxicity
|
60 |
All |
18 Years and older (Adult, Senior) |
NCT03286023 |
CYM6 Brain metastases CFB 1 |
CKBrainMeta |
October 2014 |
October 2018 |
December 2021 |
September 18, 2017 |
September 18, 2017 |
|
- Centre Francois Baclesse
Esch-sur-Alzette, SUD, Luxembourg
|
| 3 |
NCT03284151 |
Recruiting |
Focused Stereotactic Radiation Treatment of Prostatic Adenocarcinoma |
|
|
Observational |
|
- Centre Francois Baclesse, Luxembourg
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Delay between the initial diagnosis and date of salvage treatment
- PSA evaluation
- Birads score evaluation
- (and 3 more...)
|
40 |
Male |
Child, Adult, Senior |
NCT03284151 |
CYM6 Prostate CFB2 |
|
January 2015 |
January 2020 |
January 2023 |
September 15, 2017 |
September 15, 2017 |
|
- Centre Francois Baclesse
Esch Sur Alzette, Luxembourg
|
| 4 |
NCT03235557 |
Recruiting |
CyberKnife for Prostate Cancer Patients Aged 70 y or More |
|
|
Observational |
|
- Centre Francois Baclesse, Luxembourg
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Acute and late toxicity (Using the CTCAEv4)
- PSA evaluation
- Digital rectal exam
- (and 3 more...)
|
60 |
Male |
70 Years and older (Senior) |
NCT03235557 |
CYM Prostate CFB 1 |
ProRobot |
October 2014 |
October 2018 |
December 2021 |
August 1, 2017 |
August 1, 2017 |
|
- Centre Francois Baclesse
Esch Sur Alzette, Luxembourg
|
| 5 |
NCT03210129 |
Recruiting |
Motivational Interviewing to Increase Physical Activity Behaviour in Cancer Patients |
- Cancer, Breast
- Cancer of Colon
- Endometrial Cancer
|
- Behavioral: Motivational interviewing
|
Interventional |
Not Applicable |
- Luxembourg Institute of Health
- Fondation Cancer
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Change in physical activity behavior
- Body mass index
- Ramped Bruce Protocol test
- (and 3 more...)
|
70 |
All |
18 Years and older (Adult, Senior) |
NCT03210129 |
DoPH_SMRL_20161208 |
MIPAClux |
July 6, 2017 |
December 31, 2018 |
March 31, 2019 |
July 6, 2017 |
August 29, 2017 |
|
- Luxembourg Institute for Health
Luxembourg, Luxembourg
|
| 6 |
NCT03209128 |
Recruiting |
Cerebral Prophylactic Irradiation With Saving Hippocampus and Amygdala |
- Non Small Cell Lung Cancer
|
- Radiation: Irradiation prophyllactique cérébrale
|
Observational |
|
- Centre Francois Baclesse, Luxembourg
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Cognitive function
- Secondary effects according the CTCAE v.4 criteria
- Appearance of brain metastases and their location
- Quality of life (QOL) of patients
|
20 |
All |
18 Years and older (Adult, Senior) |
NCT03209128 |
IPC |
IPC |
April 20, 2017 |
December 31, 2019 |
December 31, 2019 |
July 6, 2017 |
July 6, 2017 |
|
- Centre Francois Baclesse
Esch Sur Alzette, Luxembourg
|
| 7 |
NCT03206385 |
Recruiting |
IMRT Followed by CyberKnife Boost Focused on the Gross Residual Pelvic Tumor Volume |
|
- Radiation: Radiation treatment
- Radiation: CK Boost Pelvis
|
Observational |
|
- Centre Francois Baclesse, Luxembourg
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Severe toxicity
- Local clinical control rates
- Extra pelvic dissemination rates
- Ability of the multi leaf collimator to better cover the PTVs and to help shortening the delivery times
|
120 |
All |
18 Years and older (Adult, Senior) |
NCT03206385 |
CK Boost Pelvis |
Boost_Pelvis |
May 31, 2017 |
December 31, 2023 |
December 31, 2023 |
July 2, 2017 |
July 2, 2017 |
|
- Centre Francois Baclesse
Esch-sur-Alzette, SUD, Luxembourg
|
| 8 |
NCT03199144 |
Recruiting |
Neoadjuvant Chemotherapy and Stereotactic Radiosurgery to Pancreatectomy for Patients With Borderline Resectable Pancreatic Cancer |
|
- Drug: Chemotherapy
- Radiation: Stereotactic radiotherapy
- Procedure: Surgery
|
Interventional |
Phase 2 |
- Centre Francois Baclesse, Luxembourg
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- patient overall survival
- positive surgical margins
- toxicity according the CTCAEv4
- (and 2 more...)
|
70 |
All |
18 Years and older (Adult, Senior) |
NCT03199144 |
Pancreas cancer neoadjuvant |
CKPancreas |
April 20, 2017 |
December 2023 |
December 2023 |
June 26, 2017 |
July 2, 2017 |
|
- Centre Francois Baclesse
Esch-sur-Alzette, SUD, Luxembourg
|
| 9 |
NCT03115437 |
Recruiting |
Effects of Shoe Cushioning and Body Mass on Injury Risk in Running |
- Running-Related Injury (First-time)
|
- Other: Hard cushioned running shoes
- Other: Soft cushioned running shoes
|
Interventional |
Not Applicable |
- Luxembourg Institute of Health
- DECATHLON SA
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Running-related injury (First-time)
- Running-related injury (subsequent)
- Step frequency (steps/min)
- (and 12 more...)
|
800 |
All |
18 Years to 65 Years (Adult) |
NCT03115437 |
DOPH_SMRL_20161101 |
RRI_Interv4 |
September 20, 2017 |
July 31, 2018 |
July 31, 2018 |
April 14, 2017 |
March 6, 2018 |
|
- Luxembourg Institute of Health
Luxembourg, Luxembourg
|
| 10 |
NCT03103867 |
Recruiting |
QUality of Control and slEep in Children With diabeteS, Using New Technology |
- Diabetes Mellitus, Type 1
|
- Device: CGM augmented pump with PLGS ,
- Device: Insulin pump with CGM
|
Interventional |
Not Applicable |
- Centre Hospitalier du Luxembourg
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Time in glucose target
- time below glucose target
- Time above glucose target
- (and 3 more...)
|
36 |
All |
6 Years to 14 Years (Child) |
NCT03103867 |
QUEST |
QUEST |
February 23, 2017 |
December 31, 2017 |
December 31, 2017 |
April 6, 2017 |
April 6, 2017 |
|
- Clinique des Enfants CHluxembourg
Luxembourg, Luxembourg
|
| 11 |
NCT02931955 |
Active, not recruiting |
Applying Systems Immunology to the Search for Personalized Biomarkers of Clinical Efficacy |
|
- Other: Blood draw, stool collection.
|
Observational |
|
- Luxembourg Institute of Health
- Integrated Biobank of Luxembourg
- Centre Hospitalier du Luxembourg
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Predicting the effectiveness of immunotherapy against insect venom and pollens in allergic patients with use of gene expression networks.
|
30 |
All |
18 Years and older (Adult, Senior) |
NCT02931955 |
SYS-T-ACT_01 |
SYS-T-ACT |
August 2016 |
March 2018 |
April 2018 |
October 13, 2016 |
March 6, 2018 |
|
- Centre Hospitalier de Luxembourg
Luxembourg, Luxembourg
|
| 12 |
NCT01649362 |
Completed
Has Results |
Effects of Prefeeding Oral Stimulation on Feeding Performance in Preterm Infants |
- Preterm Infant
- Oral Feeding Performance
|
- Other: prefeeding oral stimulation program
|
Interventional |
Not Applicable |
- Centre Hospitalier du Luxembourg
- Luxembourg Institute of Health
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Length of Transition Period
- Length of Hospital Stay
- Breastfeeding Rate at Discharge
|
101 |
All |
Child, Adult, Senior |
NCT01649362 |
201105/04 |
|
June 2011 |
November 2012 |
December 2012 |
July 25, 2012 |
March 12, 2014 |
December 18, 2013 |
- Service de néonatologie, Centre Hospitalier de Luxembourg
Luxembourg, Luxembourg
|
| 13 |
NCT01442805 |
Completed |
Use of Virtual Reality in the Treatment of Flying Phobia |
|
- Behavioral: Virtual Reality Exposure Therapy
- Behavioral: Exposure Therapy through Imagination
|
Interventional |
Not Applicable |
- Luxembourg Institute of Health
- Centre Hospitalier du Luxembourg
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Flight taken
- Physiological Measures
- Specific Questionnaires
|
36 |
All |
18 Years to 65 Years (Adult) |
NCT01442805 |
20080102 |
|
October 2008 |
September 2011 |
March 2012 |
September 29, 2011 |
March 15, 2017 |
|
- Centre de Recherche Public de la Santé
Strassen, Luxembourg
|
| 14 |
NCT01354236 |
Unknown † |
Mental Health Related to School Dropout in Luxembourg |
- Anxiety Disorders
- Mood Disorders
- Eating Disorders
- (and 4 more...)
|
|
Observational |
|
- Public Research Centre Health, Luxembourg
- Fonds National de la Recherche Scientifique
- Université de Liège
- (and 2 more...)
|
Other |
- Observational Model: Case Control
- Time Perspective: Cross-Sectional
|
- Prevalence and type of psychiatric disorders
- Family variables (task fulfillment,role performance, communication, affective expression, connectedness, control behaviour, values and standards)
- Socio-economic background (low, medium, high)
|
200 |
All |
16 Years to 25 Years (Child, Adult) |
NCT01354236 |
AFR-CESP-20100403 |
|
January 2011 |
|
|
May 16, 2011 |
May 16, 2011 |
|
- Public Research Centre Health
Luxembourg, Strassen, Luxembourg
|
| 15 |
NCT01146132 |
Completed |
Nutrition and Physical Activity in Patients With Cerebrovascular Disease |
- Cerebrovascular Disorders
|
- Dietary Supplement: Conventional diet +/- wine
- Dietary Supplement: Luxembourg variant of Mediterranean diet + physical activity +/- wine
|
Interventional |
Not Applicable |
- Manon Gantenbein
- Centre Hospitalier du Luxembourg
- Public Research Centre Health, Luxembourg
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
|
- Differences in mean systolic blood pressure in the two diet/sport arms
- Effects on cerebrovascular health profile
- Assessment of genetic marker and/or genetic modifications.
|
119 |
All |
30 Years and older (Adult, Senior) |
NCT01146132 |
CRP-Santé |
ALVINA |
June 2009 |
December 2011 |
December 2011 |
June 17, 2010 |
October 5, 2012 |
|
- CHL
Luxembourg, Luxembourg
|
| 16 |
NCT00195338 |
Completed
Has Results |
Study Evaluating Enbrel In Adults With Active Rheumatoid Arthritis In Luxemburg |
|
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
- Percentage of Participants With Completion of Study Treatment
- Change From Baseline in Number of Joints With Active Synovitis at Months 6, 12, 18, 30, 42, 54 and 66
- (and 2 more...)
|
25 |
All |
17 Years and older (Child, Adult, Senior) |
NCT00195338 |
0881-101343 |
|
May 2004 |
December 2010 |
December 2010 |
September 19, 2005 |
January 23, 2012 |
January 23, 2012 |
- Pfizer Investigational Site
Luxembourg, Luxembourg
|
| 17 |
NCT02099409 |
Completed |
Safety and Efficacy of Overnight Closed Loop in Children With Type 1Diabetes Mellitus in Luxembourg |
|
|
Interventional |
Not Applicable |
- Centre Hospitalier du Luxembourg
- University of Cambridge
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Time spent in normal glucose range ( mg/dl)
- glucose variability ( excursions in mg/dl)
- Time spent in low glucose range (< 60 mg/dl)
- (and 2 more...)
|
15 |
All |
6 Years to 12 Years (Child) |
NCT02099409 |
SPIDLUX 4 |
|
January 2014 |
August 2014 |
August 2014 |
March 28, 2014 |
September 16, 2014 |
|
- DECCP Clinique Pédiatrique de Luxembourg/CHL
Luxembourg, Luxembourg - DECCP Pediatric Clinic , CHLuxembourg
Luxembourg, Luxembourg
|
| 18 |
NCT01147562 |
Recruiting |
Biomarker Discovery and Validation in Lung Cancer |
|
- Procedure: Collection of biospecimen
|
Interventional |
Not Applicable |
- Dr. Guy Berchem
- Integrated Biobank of Luxembourg
- Centre Hospitalier du Luxembourg
- Public Research Centre Health, Luxembourg
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
|
- Discover and validate molecular biomarkers for lung cancer
|
150 |
All |
18 Years and older (Adult, Senior) |
NCT01147562 |
IBBL0001 |
LCS |
October 2009 |
July 2017 |
October 2020 |
June 22, 2010 |
January 19, 2017 |
|
- Centre Hospitalier de Luxembourg (CHL)
Luxembourg, Luxembourg - Clinique Sainte Thérèse (Zithaklinik)
Luxembourg, Luxembourg
|
| 19 |
NCT00775736 |
Completed |
Observational Study Evaluating the Safety of NovoMix® in Type 2 Diabetes Patients Previously Treated With a Human Premix Insulin |
- Diabetes
- Diabetes Mellitus, Type 2
|
- Drug: biphasic insulin aspart 30
- Drug: biphasic insulin aspart 50
- Drug: biphasic insulin aspart 70
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- The number of serious adverse drug reactions, including major hypoglycaemic episodes, reported during the study period.
- Number of all hypoglycaemic episodes.
- Number of all adverse drug reactions.
- (and 3 more...)
|
611 |
All |
Child, Adult, Senior |
NCT00775736 |
BIASP-3665 |
Mix2Mix |
October 2008 |
January 2011 |
January 2011 |
October 20, 2008 |
January 11, 2017 |
|
- Novo Nordisk Investigational Site
Brussels, Belgium - Novo Nordisk Investigational Site
Luxembourg, Luxembourg
|
| 20 |
NCT00709917 |
Completed |
Observational Study of the Switch of Metformin Alone to Metformin Combined With Repaglinide in Type 2 Diabetes |
- Diabetes
- Diabetes Mellitus, Type 2
|
|
Observational |
|
|
Industry |
- Time Perspective: Prospective
|
- Safety (number of hypoglycaemic incidents)
- HbA1C
- safety
- (and 3 more...)
|
2171 |
All |
18 Years and older (Adult, Senior) |
NCT00709917 |
AGEE-1857 |
REPAMET |
March 2007 |
January 2008 |
January 2008 |
July 3, 2008 |
March 3, 2016 |
|
- Brussels, Belgium
- Luxembourg, Luxembourg
|
| 21 |
NCT02525562 |
Active, not recruiting |
Stryker NTX Registry Scorpio NRG (Re-"Energize"), Triathlon Total Knee, Triathlon Partial Knee Resurfacing (PKR) With X3 Polyethylene Insert |
- Arthroplasty, Replacement, Knee
|
- Device: Triathlon Total Knee System with X3 insert
- Device: Scorpio NRG Total Knee System with X3 insert
- Device: Triathlon PKR System with X3 insert
|
Interventional |
Not Applicable |
- Stryker European Operations BV
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Survivorship of the device
- Investigation of clinical performance and patient outcome with the Knee Society Score (KSS)
- Investigation of clinical performance and patient outcome with the Knee Injury and Osteoarthritis Outcome Score (KOOS) patient questionnaire.
- Investigation of clinical performance and patient outcome with the EuroQuol-5 dimension health questionnaire (EQ-5D) patient questionnaire.
|
224 |
All |
Child, Adult, Senior |
NCT02525562 |
K-S-044 |
NTX |
June 2012 |
March 2024 |
March 2024 |
August 17, 2015 |
November 30, 2017 |
|
- Kliniken Dr. Erler gGmbH
Nürnberg, Bayern, Germany - Centre Hospitalier de Luxembourg
Luxembourg, Luxembourg - Worcestersire Acute Hospital NHS Trust, Alexandra Hospital
Redditch, Worcestersire, United Kingdom
|
| 22 |
NCT00534261 |
Completed |
Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a? |
- Relapsing Remitting Multiple Sclerosis
|
|
Interventional |
Phase 4 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The primary objective of this study is to evaluate the correlation between the MS Functional Composite Index and two Quality of Life scales (MS Quality of Life 54 and AMS Quality of Life) in patients treated with interferon beta-1a (AVONEX®).
- Reproducibility of Quality of Life scales per language version
- Reliability of the Quality of Life scales per language version
- EDSS score throughout the study
|
284 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT00534261 |
BIO-BNL 99-01 |
FLAIR |
November 1999 |
|
February 2004 |
September 24, 2007 |
December 13, 2007 |
|
- Coordinating Research Site
Sijsele-Damme, Belgium - Coordinating Research Site
Esch-Sur-Alzette, Luxembourg - Coordinating Research Site
Glasgow, Scotland, United Kingdom
|
| 23 |
NCT00117780 |
Completed |
Comparison of Insulin Detemir Given Once or Twice Daily in Type 1 Diabetes |
- Diabetes
- Diabetes Mellitus, Type 1
|
- Drug: insulin detemir
- Drug: insulin aspart
|
Interventional |
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Mean HbA1c
- HbA1c
- Adverse events
- (and 4 more...)
|
520 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT00117780 |
NN304-1708
2005-001522-88 |
ADAPT |
June 2005 |
October 2006 |
October 2006 |
July 8, 2005 |
June 2, 2017 |
|
- Novo Nordisk Investigational Site
Aalst, Belgium - Novo Nordisk Investigational Site
Lille, France - Novo Nordisk Investigational Site
Luxembourg, Luxembourg
|
| 24 |
NCT00681850 |
Completed |
OPtimal Type 2 dIabetes Management Including Benchmarking and Standard trEatment. |
|
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- HbA1c, LDL-cholesterol, Systolic Blood Pressure
- Glycaemia, Triglycerides, Total and HDL-Cholesterol, Diastolic Blood Pressure, Waist circumference, Smoking habits, Microalbuminuria, Body Mass Index, Physical activity (Rating scale and step counter), Degree of ophthalmic control and dietary advice
|
4027 |
All |
18 Years and older (Adult, Senior) |
NCT00681850 |
D3560L00071 |
Optimise |
March 2008 |
January 2010 |
January 2010 |
May 21, 2008 |
June 2, 2010 |
|
- Research Site
Aalst, Belgium - Research Site
Aarschot, Belgium - Research Site
Alsemberg, Belgium - (and 249 more...)
|
| 25 |
NCT01081873 |
Completed
Has Results |
Study to Document Treatment Patterns and to Evaluate Leuprolide and Alternative Therapeutic Approaches to the Treatments of Advanced Prostate Cancer |
|
- Drug: leuprolide (Lucrin/Lucrin-Tri-depot)
|
Observational |
|
|
Industry |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Effectiveness Parameter for Staging of Prostate Cancer: Metastases at Each Visit
- Effectiveness Parameter for Screening or Recurrence of Prostate Cancer: Mean Prostate-specific Antigen (PSA) at Each Visit
- Effectiveness Parameter: the Number of Participants With a Complete or Partial Response, Stable Disease, or Progressive Disease Following Treatment at Each Visit
- (and 14 more...)
|
2717 |
Male |
18 Years and older (Adult, Senior) |
NCT01081873 |
PMOS-BELG-04-001 |
|
June 2004 |
December 2010 |
December 2010 |
March 5, 2010 |
October 31, 2012 |
March 26, 2012 |
- Site Reference ID/Investigator# 31196
Aartselaar, Belgium - Site Reference ID/Investigator# 31237
Afsnee, Belgium - Site Reference ID/Investigator# 31121
Alken, Belgium - (and 132 more...)
|
| 26 |
NCT01078558 |
Completed |
A Belgian Registry of HUMIRA® (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis |
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Ankylosing Spondylitis
|
|
Observational |
|
- AbbVie (prior sponsor, Abbott)
- Veeda Clinical Research
- AbbVie
|
Industry |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Swollen and tender joint count, C reactive protein, Erythrocyte sedimentation rate, Health assessment questionnaire, Body surface area with psoriasis, numerical rating scale, Bath ankylosing spondylitis disease activity index, concomitant medication
- Safety parameters/ SAE reporting
|
5832 |
All |
18 Years to 99 Years (Adult, Senior) |
NCT01078558 |
HUM04-28 |
ProAct |
May 13, 2004 |
January 11, 2018 |
January 11, 2018 |
March 2, 2010 |
January 17, 2018 |
|
- CHC Liege
Liège, Liege, Belgium - Algemeen Stedelijk Ziekenhuis
Aalst, Oost-Vlaanderen, Belgium - Reumacentrum
Aalst, Belgium - (and 115 more...)
|
| 27 |
NCT00290264 |
Completed |
SALTO - Symbicort Single Inhaler Therapy Use in Adolescent Adults and Adults With Persistent Asthma |
|
- Drug: Budesonide/formoterol
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Time to first severe asthma exacerbation
- Number of severe asthma exacerbations
- Mean use of as-needed medication
- (and 2 more...)
|
1000 |
All |
12 Years and older (Child, Adult, Senior) |
NCT00290264 |
D5890L00009
Eudract No: 2004-001107-36
SALTO |
|
December 2004 |
|
August 2006 |
February 13, 2006 |
January 24, 2011 |
|
- Research Site
Aalst, Belgium - Research Site
Aartrijke, Belgium - Research Site
Alsemberg, Belgium - (and 207 more...)
|
| 28 |
NCT01161173 |
Completed
Has Results |
An Observational Study of Tarceva (Erlotinib) in Routine Daily Clinical Practice as Second Line Treatment in Patients With Non-small Cell Lung Cancer |
- Nonsquamous Nonsmall Cell Neoplasm of Lung
|
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD)
- Time to Disease Progression
- Progression-free Survival
- (and 3 more...)
|
347 |
All |
18 Years and older (Adult, Senior) |
NCT01161173 |
ML21474 |
TEAM |
April 2008 |
August 2012 |
August 2012 |
July 13, 2010 |
March 28, 2016 |
March 28, 2016 |
- Aalst, Belgium
- Antwerpen, Belgium
- Arlon, Belgium
- (and 34 more...)
|
| 29 |
NCT00571649 |
Completed
Has Results |
Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients |
|
- Drug: Rivaroxaban (Xarelto, BAY59-7939)
- Drug: Enoxaparin
- Drug: Rivaroxaban placebo
- Drug: Enoxaparin placebo
|
Interventional |
Phase 3 |
- Bayer
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Percentage of Participants With Composite Endpoint of Venous Thromboembolism [VTE] (Any Deep Vein Thrombosis [DVT], Non Fatal Pulmonary Embolism [PE]) and VTE-related Death up to Day 35 + 6 Days
- Percentage of Participants With Composite Endpoint of VTE (Any DVT, Non Fatal PE) and VTE-related Death up to Day 10 + 5 Days
- Percentage of Participants With Composite Endpoint of VTE (Any DVT, Non Fatal PE) and All-cause Mortality up to Day 35 + 6 Days
- (and 11 more...)
|
8101 |
All |
40 Years and older (Adult, Senior) |
NCT00571649 |
12839
2007-004614-14 |
MAGELLAN |
December 2007 |
August 2010 |
November 2010 |
December 12, 2007 |
September 15, 2016 |
June 27, 2012 |
- Birmingham, Alabama, United States
- Birmingham, Alabama, United States
- Dothan, Alabama, United States
- (and 673 more...)
|
| 30 |
NCT02367040 |
Recruiting |
Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) |
|
- Drug: Copanlisib (BAY 80-6946)
- Drug: Placebo
- Drug: Rituximab
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Progression free survival (PFS)
- Objective tumor response
- Duration of response (DOR)
- (and 6 more...)
|
450 |
All |
18 Years and older (Adult, Senior) |
NCT02367040 |
17067
2013-003893-29 |
CHRONOS-3 |
August 3, 2015 |
March 31, 2020 |
August 28, 2020 |
February 20, 2015 |
April 3, 2018 |
|
- West Covina, California, United States
- Whittier, California, United States
- Denver, Colorado, United States
- (and 282 more...)
|
| 31 |
NCT02279654 |
Recruiting |
Non-interventional Study of Lenalidomide in the Clinical Routine Treatment of TD Patients With IPSS Low or Int-1 MDS and Isolated Del(5q) |
|
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Ascertain the Disease Progression to AML (through calculation of product limit estimators and incidence rates) for those with transfusion dependent Low to Intermediate 1 risk MDS del 5 q and have been treated with Revlimid
- Overall Survival for patients with transfusion-dependent low to intermediate 1 risk MDS and isolated del (5q) and who have been treated with Lenalidomide
- Adverse Events
- (and 2 more...)
|
1800 |
All |
18 Years and older (Adult, Senior) |
NCT02279654 |
CC-5013-MDS-010 |
PASS MDS del5q |
December 17, 2014 |
December 31, 2021 |
December 31, 2022 |
October 31, 2014 |
November 14, 2017 |
|
- AZ Klina
Brasschaat, Belgium - AZ Sint Jan
Brugge, Belgium - Hospital Erasm - 808 Route de lennik
Brussels, Belgium - (and 164 more...)
|
| 32 |
NCT02236637 |
Recruiting |
A Registry to Observe the Treatment of Prostate Cancer Under Routine Medical Care |
|
|
Observational |
|
- Janssen Pharmaceutica N.V., Belgium
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Sequencing of treatment initiation, termination, and duration
- Clinical Benefit
- Medical Resource Utilization
- (and 7 more...)
|
3000 |
Male |
18 Years and older (Adult, Senior) |
NCT02236637 |
CR100857
212082PCR4001 |
|
June 14, 2013 |
June 30, 2018 |
December 14, 2018 |
September 10, 2014 |
April 5, 2018 |
|
- St.Johanns Spital/Landeskrankenhaus Salzburg
Salzburg, Austria - Medical University Vienna
Vienna, Austria - OLVZ Aalst
Aalst, Belgium - (and 239 more...)
|
| 33 |
NCT01381874 |
Active, not recruiting |
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy |
- Metastatic ER+ Her2- Breast Cancer
- Postmenopausal
|
- Drug: Exemestane
- Drug: Abiraterone acetate + Prednisone/ Prednisolone + Exemestane
- Drug: Abiraterone acetate + Prednisone or Prednisolone
|
Interventional |
Phase 2 |
- Janssen Research & Development, LLC
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression free survival
- Overall survival
- Overall response rate to treatment
- (and 3 more...)
|
299 |
Female |
18 Years and older (Adult, Senior) |
NCT01381874 |
CR018286
212082BCA2001
2011-000621-80 |
|
August 24, 2011 |
May 9, 2017 |
September 30, 2018 |
June 27, 2011 |
December 11, 2017 |
|
- Muscle Shoals, Alabama, United States
- Fresno, California, United States
- Los Angeles, California, United States
- (and 82 more...)
|
| 34 |
NCT00858364 |
Terminated |
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy |
- Non-Small Cell Lung Cancer
- Anemia
- Cancer
- Lung Cancer
|
- Drug: darbepoetin alfa 500 mcg Q3W
- Drug: placebo
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Supportive Care
|
- Overall survival (OS)
- Incidence of neutralizing antibody formation to darbepoetin alfa
- Incidence of at least 1 Red Blood Cell (RBC) transfusion or hemoglobin less than or equal to 8.0 g/dL from study day 1 to end of efficacy treatment period
- (and 5 more...)
|
2549 |
All |
18 Years and older (Adult, Senior) |
NCT00858364 |
20070782 |
|
July 17, 2009 |
June 7, 2017 |
June 7, 2017 |
March 9, 2009 |
December 2, 2017 |
|
- Research Site
Anniston, Alabama, United States - Research Site
Birmingham, Alabama, United States - Research Site
Anchorage, Alaska, United States - (and 629 more...)
|
| 35 |
NCT00545909 |
Completed |
BEATRIS Study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis |
- Postmenopausal Osteoporosis
|
- Drug: ibandronate [Bonviva/Boniva]
|
Interventional |
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Comparison of percentage of patients with >=83% adherence to Bonviva in feedback vs no feedback group
- Patient satisfaction by OPSAT-Q and OPPS.
- Tolerability; SAEs.
|
585 |
Female |
55 Years to 85 Years (Adult, Senior) |
NCT00545909 |
ML19913 |
|
March 2006 |
August 2008 |
August 2008 |
October 17, 2007 |
November 2, 2016 |
|
- Bregenz, Austria
- Graz, Austria
- Innsbruck, Austria
- (and 54 more...)
|
| 36 |
NCT02720757 |
Terminated |
Assessment of Physical Functioning and Handling of Spiolto Respimat in Patients With COPD (OTIVACTO) |
- Pulmonary Disease, Chronic Obstructive
|
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Changes in physical functioning based on PF-10 scores
- Patients' satisfaction with Spiolto Respimat using a Patient Satisfaction Survey
- Patients' general condition using the Physician's Global Evaluation (PGE) scale
|
132 |
All |
40 Years and older (Adult, Senior) |
NCT02720757 |
1237.45 |
|
August 26, 2016 |
December 14, 2017 |
December 14, 2017 |
March 28, 2016 |
March 13, 2018 |
|
- Multiple Locations, Belgium
- Multiple Locations, Denmark
- Multiple Locations, Luxembourg
- (and 3 more...)
|
| 37 |
NCT03247023 |
Recruiting |
Long Term Follow-up of Integra® Cadence™ Total Ankle System in Primary Ankle Joint Replacement |
- Degenerative Arthritis
- Rheumatoid Arthritis
- Traumatic Arthritis
|
- Device: Implantation of Integra Cadence Total Ankle Sysyem
|
Observational |
|
- Integra LifeSciences Corporation
- Integra LifeSciences Services
|
Industry |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Implant survivorship
- Relative change of Patient Reported Outcomes Measurement Information System (PROMIS) Physical Function (PF) - Mobility compared to baseline
- Relative change of Range of Motion (ROM) compared to baseline
- (and 3 more...)
|
60 |
All |
18 Years and older (Adult, Senior) |
NCT03247023 |
T-CTAS-002 |
|
September 18, 2017 |
September 2021 |
September 2029 |
August 11, 2017 |
February 16, 2018 |
|
- Universitair Ziekenhuis Gent
Gent, Belgium - Foot and Ankle Institute
Woluwe-St-Lambert, Belgium - St. Michael's Hospital
Toronto, Canada - (and 3 more...)
|
| 38 |
NCT01565967 |
Completed |
Registry AutoLog Lipid Removal and Blood Component Characterization |
|
|
Observational |
|
- Medtronic Bakken Research Center
- Medtronic Cardiovascular
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- level of reduction of nonemulsified fat
|
199 |
All |
Child, Adult, Senior |
NCT01565967 |
AutoLog |
|
December 2011 |
March 2013 |
March 2013 |
March 29, 2012 |
October 29, 2015 |
|
- Azienda Ospedaliera Universitaria Materdomini
Catanzaro, Italy - Vilnius University Hospital Santariskiu Klinikos
Vilnius, Lithuania - Institut national de chirurgie cardiaque et de cardiologie interventionnelle (INCCI)
Luxembourg, Luxembourg - (and 3 more...)
|
| 39 |
NCT01874002 |
Active, not recruiting |
Prospective Registry to Asses the Long-term Safety and Performance of the Combo Stent |
|
|
Observational |
|
- Robbert J de Winter
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Adjudicated Target Lesion Failure
- Individual components of target lesion failure (TLF)
- Adjudicated patient-oriented composite Major Adverse Cardiac Events (MACE)
- (and 4 more...)
|
1000 |
All |
18 Years and older (Adult, Senior) |
NCT01874002 |
W12_186
Version 2.0 |
REMEDEE Reg |
June 2013 |
March 2015 |
March 2019 |
June 10, 2013 |
December 30, 2015 |
|
- Pauls Stradins Clinical University Hospital
Riga, Latvia - Centre Hospitalier de Luxembourg
Luxembourg, Luxembourg - Academic Medical Center - University of Amsterdam
Amsterdam, Netherlands - (and 6 more...)
|
| 40 |
NCT03101865 |
Recruiting |
The Artificial Pancreas in Very Young Children With T1D - Pilot (KidsAP01) |
|
|
Interventional |
Not Applicable |
- University of Cambridge
- European Commission
- Medtronic
- (and 8 more...)
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Time in target (3.9 to 10.0mmol/l) (70 to 180 mg/dl)
- Time spent below target glucose (3.9mmol/l)(70mg/dl)
- Time spent above target glucose (10.0mmol/l) (180mg/dl)
- (and 10 more...)
|
30 |
All |
1 Year to 7 Years (Child) |
NCT03101865 |
KidsAP01 |
|
August 8, 2017 |
May 2018 |
May 2018 |
April 5, 2017 |
March 1, 2018 |
|
- Department of Pediatrics and Adolescent Medicine, Medical University of Graz
Graz, Austria - Department of Pediatrics I, Medical University of Innsbruck
Innsbruck, Austria - Deptartment of Pediatrics, Medical University of Vienna
Vienna, Austria - (and 4 more...)
|
| 41 |
NCT03475238 |
Recruiting |
Analysis of Factors Related to Occurrence of Serious Adverse Events During Nursing in Intensive Care Units |
- Nursing Caries
- Critical Care
|
|
Observational |
|
- French Society for Intensive Care
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Incidence of occurrence of at least one serious avderse event (SAE) (defined below) during the nursing care while the study period (72 hours)
|
200 |
All |
Child, Adult, Senior |
NCT03475238 |
2018-A00046-49 |
NURSIE |
March 29, 2018 |
June 30, 2018 |
October 1, 2018 |
March 23, 2018 |
March 30, 2018 |
|
- Hopital de Bruxelles
Bruxelles, Belgium - CHU Charleroi
Charleroi, Belgium - CHU Charleroi
Charleroi, Belgium - (and 26 more...)
|
| 42 |
NCT03052309 |
Recruiting |
BIOLUX P-III BENELUX All-Comers Registry |
- Peripheral Arterial Disease
|
- Device: Passeo-18 Lux DCB
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Freedom from Major Adverse Events (MAE)
- Freedom from clinically driven target lesion revascularization (cd-TLR)
- Freedom from clinically-driven target lesion revascularization (cd-TLR)
- (and 10 more...)
|
100 |
All |
18 Years and older (Adult, Senior) |
NCT03052309 |
C1604 |
|
February 27, 2017 |
February 2019 |
February 2020 |
February 14, 2017 |
September 27, 2017 |
|
- Ziekenhuis Oost Limburg Genk
Genk, Belgium - University Hospital Gent (UZ Gent)
Gent, Belgium - Algemeen Ziekenhuis Groeninge Kortrijk
Kortrijk, Belgium - (and 6 more...)
|
| 43 |
NCT03289273 |
Recruiting |
Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC) |
|
- Drug: Regorafenib (Stivarga, BAY73-4506)
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Number of patients with treatment emergent adverse events (TEAEs) leading to dose modifications (including reductions, interruptions and permanent discontinuation)
- Overall survival (OS)
- Progression-free survival (PFS)
- (and 3 more...)
|
1000 |
All |
Child, Adult, Senior |
NCT03289273 |
19244 |
|
September 13, 2017 |
July 30, 2022 |
October 1, 2022 |
September 20, 2017 |
April 5, 2018 |
|
- Mercy Medical Center
Baltimore, California, United States - Henry Ford Health System
Detroit, Michigan, United States - Many locations
Multiple Locations, Albania - (and 26 more...)
|
| 44 |
NCT03191786 |
Recruiting |
A Study of Atezolizumab Compared With Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Containing Therapy |
- Non-Small Cell Lung Cancer
|
- Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
- Drug: Vinorelbine
- Drug: Gemcitabine
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Survival
- Percentage of Participants Who Are Alive at Specified Timepoints
- Percentage of Participants With Objective Response, as Determined by the Investigator Using Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 (v1.1)
- (and 7 more...)
|
441 |
All |
18 Years and older (Adult, Senior) |
NCT03191786 |
MO29872
2015-004105-16 |
IPSOS |
September 11, 2017 |
January 20, 2021 |
January 20, 2021 |
June 19, 2017 |
April 17, 2018 |
|
- Fundacion Investigar
Caba, Argentina - Hospital Privado de Comunidad
Mar del Plata, Argentina - Centro de Investigacion; Clinica - Clinica Viedma S.A.
Viedma, Argentina - (and 83 more...)
|
| 45 |
NCT02907463 |
Completed |
EDWARDS INTUITY Elite Valve System |
- Aortic Valve Disease
- Aortic Stenosis
|
|
Observational |
|
|
Industry |
- Observational Model: Other
- Time Perspective: Other
|
- Cross Clamp Time
- Operative Adverse Events
|
273 |
All |
18 Years and older (Adult, Senior) |
NCT02907463 |
2015-05 |
MISSION |
February 2016 |
April 2017 |
December 2017 |
September 20, 2016 |
March 1, 2018 |
|
- Universitätsklinik für Herzchirurgie Medizinische Universität Innsbruck
Innsbruck, Austria - Klinisshe Abteiluing Für Herz-thoraxchirurgie
Vienna, Austria - Aarhus Universitets Hospital Skejby
Aarhus N, Denmark - (and 20 more...)
|
| 46 |
NCT02830477 |
Recruiting |
Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis |
|
- Biological: Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973
|
Observational |
|
|
Industry |
- Observational Model: Other
- Time Perspective: Prospective
|
- Proportion of patients on 2x weekly prophylaxis
- Proportion of patients on 3x weekly prophylaxis
- Composite number of reported bleeds (total, spontaneous, joint and trauma)
- (and 8 more...)
|
350 |
Male |
Child, Adult, Senior |
NCT02830477 |
18559
KV1601 |
TAURUS |
October 14, 2016 |
January 31, 2020 |
June 30, 2020 |
July 13, 2016 |
April 3, 2018 |
|
- Children's Rehabilitation Services/ University of South Alabama
Mobile, Alabama, United States - University of Colorado Hemophilia and Thrombosis Center
Aurora, Colorado, United States - University of Florida Health Cancer Center
Gainesville, Florida, United States - (and 24 more...)
|
| 47 |
NCT02785900 |
Terminated |
Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia |
|
- Drug: 33A
- Drug: placebo
- Drug: azacitidine
- Drug: decitabine
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Overall survival
- Composite complete remission rate
- Minimal residual disease (MRD)-negative composite complete remission rate
- (and 7 more...)
|
240 |
All |
18 Years and older (Adult, Senior) |
NCT02785900 |
SGN33A-005
2015-003482-28 |
CASCADE |
May 2016 |
October 3, 2017 |
October 3, 2017 |
May 30, 2016 |
January 5, 2018 |
|
- University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States - City of Hope National Medical Center
Duarte, California, United States - Pacific Hematology Oncology Associates
San Francisco, California, United States - (and 125 more...)
|
| 48 |
NCT02737501 |
Active, not recruiting |
ALTA-1L Study: A Phase 3 Study of Brigatinib Versus Crizotinib in ALK-positive Advanced Non-Small Cell Lung Cancer Patients |
- Non-small Cell Lung Cancer
- Lung Cancer
- Advanced Malignancies
- Carcinoma
|
- Drug: Brigatinib
- Drug: Xalkori (crizotinib)
|
Interventional |
Phase 3 |
- Ariad Pharmaceuticals
- Takeda
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free survival (PFS) as assessed by a blinded Independent Review Committee (bIRC)
- Objective response rate (ORR)
- Intracranial ORR
- (and 9 more...)
|
270 |
All |
18 Years and older (Adult, Senior) |
NCT02737501 |
AP26113-13-301 |
ALTA-1L |
April 30, 2016 |
April 30, 2019 |
April 30, 2021 |
April 14, 2016 |
February 6, 2018 |
|
- Kaiser Permanente Southern California, Site #208
San Diego, California, United States - Innovative Clinical Research Institute (Site 243)
Whittier, California, United States - University of Colorado Cancer Center
Aurora, Colorado, United States - (and 121 more...)
|
| 49 |
NCT02699736 |
Enrolling by invitation |
Clinical and Virological Outcome of European Patients Infected With HIV |
- HIV
- Hepatitis B
- Hepatitis C
- (and 10 more...)
|
|
Observational |
|
- Rigshospitalet, Denmark
- University College, London
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Incidence of long-term virological, immunological and morbidity and mortality outcomes across different regions in Europe; and demographic, clinical, therapeutic and viral factors associated with these outcomes
- Number of patients experiencing HIV-related events over time
- Number of participants experiencing HIV-related events by region
- (and 7 more...)
|
20852 |
All |
16 Years and older (Child, Adult, Senior) |
NCT02699736 |
The EuroSIDA Study
QLK2-2000-00773
LSHC-CT-2006-018632
Gilead EuroSIDA
GSK EuroSIDA
Janssen EuroSIDA
CT94-1637
CT97-2713
Pfizer EuroSIDA
Merck EuroSIDA
BMS EuroSIDA
SNSF 108787 |
EuroSIDA |
January 1994 |
December 2030 |
December 2030 |
March 4, 2016 |
March 4, 2016 |
|
- Hospital JM Ramos Mejia
Buenos Aires, Argentina - Medical University Insbruck
Innsbruck, Austria - Otto Wagner Spital
Vienna, Austria - (and 107 more...)
|
| 50 |
NCT02671422 |
Recruiting |
LUME BioNIS: a Biomarker Study in Patients With NSCLC |
- Carcinoma, Non-Small-Cell Lung
|
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Overall Survival
- Disease progression
|
380 |
All |
18 Years and older (Adult, Senior) |
NCT02671422 |
1199.223 |
|
March 9, 2016 |
November 1, 2021 |
November 1, 2021 |
February 2, 2016 |
April 17, 2018 |
|
- LKH Klagenfurt am Woerthersee
Klagenfurt Am Woerthersee, Austria - LK Krems
Krems, Austria - KH der Barmherzigen Schwestern
Ried im Innkreis, Austria - (and 73 more...)
|
Create an RSS feed from your search for:
Download the search results for: